ImmuPharma (LON:IMM) Announces Earnings Results

ImmuPharma (LON:IMM) posted its quarterly earnings data on Wednesday. The company reported GBX (0.37) earnings per share for the quarter, Digital Look Earnings reports. ImmuPharma had a negative return on equity of 6,634.51% and a net margin of 3,519.56%.

ImmuPharma Trading Up 4.3%

LON:IMM opened at GBX 4.70 on Wednesday. ImmuPharma has a 12 month low of GBX 1.39 and a 12 month high of GBX 19.40. The stock has a 50 day moving average of GBX 4.63 and a two-hundred day moving average of GBX 6.31. The firm has a market cap of £29.29 million, a P/E ratio of -5.28 and a beta of 2.98.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.